The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Impressive results for R-BAC post BTKi in R/R MCL
Effective treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) post ibrutinib therapy represents an unmet clinical need. Simon Rule, MD, Plymouth University, Plymouth, UK, discusses the use of R-BAC (rituximab, bendamustine and cytarabine) in the post-Bruton’s tyrosine kinase inhibitor (BTKi) setting. Results from the study support R-BAC being considered a new standard of care option for R/R MCL post ibrutinib. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
